📖 Approx. 11 min read ／ Updated 2026.05.08
When considering the business succession of a medical corporation or the M&A of a clinic, one of the most important and delicate elements is “confidentiality.” There is always a risk of significant negative impact on management if information about the M&A consideration stage leaks to patients, staff, or business partners. This article delves deeply into the importance of confidentiality in medical M&A, explaining concrete practices and industry-specific considerations, from the proper use of Non-Disclosure Agreements (NDAs) to managing information disclosure to stakeholders and responding to potential leaks.
Importance and Background of Confidentiality in Medical M&A
Compared to M&A in general corporations, the importance of confidentiality in M&A of medical institutions is significantly higher. This is due to the public nature of medical services and their direct connection to people’s lives and health. If information regarding M&A consideration were to leak externally, it could lead to the following serious situations:
- Risk of Patient Attrition: Patients may transfer to other medical institutions due to anxiety about changes in management structure. This impact can be particularly severe when patients’ trust is based on a specific doctor or medical corporation.
- Staff Turnover: Uncertainty about the future of the medical institution can cause significant distress among doctors, nurses, and administrative staff. The departure of key medical personnel can make it difficult to maintain the medical care system and may even affect compliance with facility standards.
- Deterioration of Transaction Terms: There is a possibility that existing favorable transaction terms with business partners, such as pharmaceutical wholesalers, medical equipment manufacturers, and property owners with whom lease agreements are in place, may not be maintained.
- Reputational Damage and Brand Value Erosion: Information based on speculation or misunderstanding may spread, potentially damaging the reputation and brand image of the medical institution that has been built over many years.
- Impact on Licenses and Permits: Licenses and permits under the Medical Care Act are granted based on a stable medical care provision system. There is a non-zero possibility that confusion caused by information leaks could lead to administrative guidance or, in the worst case, a review of licenses and permits.
Especially for medical corporations without share capital or those funded by contributions, changes in members (e.g., chairman, directors) are fundamental to management, making such information extremely confidential. Early information leaks not only risk the breakdown of the M&A itself but also pose a threat to the continuation of existing operations. Therefore, establishing a thorough confidentiality system is key to success.
Timing and Legal Validity of Signing a Non-Disclosure Agreement (NDA)
In the medical M&A process, a Non-Disclosure Agreement (NDA) is a fundamental legal document governing the handling of information. Understanding the appropriate timing and content of an NDA is essential for mitigating risks for both parties.
Standard Timing for Signing an NDA
- At or immediately after the initial consultation with an M&A advisor: When considering the sale of a medical institution, one typically first consults with an M&A advisor. At this stage, confidential information such as the name and general overview of the medical institution may already be disclosed. Therefore, it is common to sign an NDA with the advisor to ensure the confidentiality of consultation details.
- Before disclosing information to potential acquirers: After signing an NDA with the advisor and proceeding with matching with specific potential acquirers, an NDA is signed with the potential acquirer before disclosing detailed information about the selling medical institution (e.g., business details, financial status, patient numbers, trends in medical fees, facility standards held). This is crucial to prevent information from being mixed up or used for other purposes, even if the potential acquirer is considering multiple M&A deals.
Legal Validity and Key Provisions of an NDA
An NDA clearly defines the scope of disclosed confidential information, its purpose of use, the duration of the confidentiality obligation, the obligation to return or destroy confidential information, and the measures to be taken in case of breach (e.g., claims for damages). In medical M&A, a “mutual NDA” that imposes confidentiality obligations on both the seller and the buyer is the general principle. This allows the seller to protect their own information while also protecting information that may be disclosed by the potential acquirer (e.g., parts of the acquirer’s business strategy or financial status).
If an NDA breach is discovered, claims for damages as stipulated in the contract can be made, but calculating the actual damages can often be complex. Therefore, it is common to include penalty clauses or predetermined damages in the NDA to serve as a deterrent. Information such as data analyzing the impact of medical fee revisions, considerations on the institution’s position within regional healthcare plans, and know-how for meeting specific facility standards can also be important confidential information to be protected by an NDA.
Disclosure and Management of Information to Internal Stakeholders
One of the most challenging aspects of M&A confidentiality is managing information disclosure to individuals within the medical institution. Leaks from within, as well as external leaks, can fuel anxiety among patients and staff, negatively impacting the M&A process.
Optimizing the Scope and Timing of Information Disclosure
The golden rule for disclosing information to internal stakeholders is to do so to the minimum necessary individuals at the minimum necessary time. In the initial stages, it is effective to limit disclosure to a core team essential for M&A consideration and preparation, such as the chairman, director, spouse, and the person in charge of accounting for the corporation, and to have them sign individual confidentiality agreements.
- Notification to Staff: General notification to staff typically occurs after the signing of a Letter of Intent (LOI) or just before the signing of the final agreement (SPA). This is done to minimize staff anxiety by disclosing information only when the direction of the M&A is firm and details about the post-succession structure and treatment can be explained. During notification, it is important to carefully explain employment conditions, medical policies, and benefits after succession to gain the understanding and cooperation of the staff.
- Consideration for Key Personnel: In some cases, key personnel essential for post-M&A management, such as vice directors, administrative directors, or heads of specific departments, may be informed individually and earlier than other staff. In such cases, they should also be bound by confidentiality obligations similar to an NDA, and thorough measures should be taken. Their departure can directly impact the “change of members” in a medical corporation or the continuation of highly specialized departments, requiring careful handling.
Thorough Information Management
It is essential to implement both physical and electronic security measures for M&A-related documents and data, such as storing them in lockable cabinets or managing them as password-protected digital files. Discussions related to M&A should be held in places where they cannot be overheard externally, and casual information exchange should be avoided. Even among internal stakeholders, aligning awareness and providing training on information handling can reduce the risk of leaks.
Security Measures for Information Sharing with Potential Acquirers
When sharing detailed information with potential acquirers, robust security measures are required to ensure that the information is properly managed and not used improperly. In medical M&A, in particular, it is crucial to handle extremely confidential information such as patient data (anonymized/aggregated), medical fee claim data, facility standard documents, and employee personal information with the utmost care.
Utilizing a Virtual Data Room (VDR)
In modern M&A practices, the use of a “Virtual Data Room (VDR)” is common as a secure platform for sharing information. A VDR is a secure platform for sharing confidential documents over the internet and significantly reduces the risk of information leaks through functions such as:
- Strict Access Control: Granular permission settings can be configured, determining who can access which information and whether they can only view or also download it. Access rights are granted to each representative of the potential acquirer to restrict access to unnecessary information.
- Access Log Recording: All operation histories, including who accessed or downloaded which document and when, are recorded. This makes it easier to identify the source in case of a leak and acts as a deterrent against unauthorized access.
- Watermark Function: This feature automatically inserts the viewer’s name, date, and time as a watermark on downloaded documents. This makes it easier to identify the source if the information is leaked externally.
- Print and Download Restrictions: For highly confidential information, settings can be configured to prohibit printing and downloading, limiting viewing to within the VDR.
- Centralized Information Management and Version Control: Numerous documents and data are managed centrally without dispersion, and the latest versions are always shared, preventing misinterpretation and confusion of information.
A VDR not only ensures the security of information provided by the seller but also offers the advantage of allowing the buyer to efficiently and safely review necessary information. However, what information to disclose and to what extent varies depending on the stage of due diligence and the reliability of the potential acquirer, making it important to make decisions in close cooperation with an M&A advisor.
Response to Breach of Confidentiality Obligation and Damages
No matter how stringent the measures taken, unfortunately, the possibility of a breach of confidentiality obligation cannot be eliminated. In the event of an information leak, prompt and appropriate action is crucial to prevent the escalation of damages and to resolve the situation.
Initial Response Upon Discovery of Breach
- Fact-Finding and Cause Investigation: Quickly identify what information was leaked, when, from where, by whom, and how. The first step is to grasp the detailed situation through VDR access logs and interviews with internal stakeholders.
- Assessment of Damages: Based on the nature and scope of the leaked information, assess the actual or potential damages, such as patient attrition, staff turnover, reputational damage, and deterioration of transaction terms. It is particularly important to quickly estimate the concrete financial impact, such as a decrease in medical fees or an increase in business taxes.
- Halting Information Leak and Preventing Spread: Identify the source of the leak and take measures to prevent further dissemination of the information. If necessary, consider warning relevant parties and requesting the removal of information from the internet.
Legal Action and Claims for Damages
If a breach of the NDA is clearly established, the seller can take the following legal actions against the potential acquirer based on the provisions of the NDA:
- Injunction: Request the cessation of use or disclosure of the leaked information.
- Claim for Damages: Claim compensation for damages incurred due to the leak (e.g., lost profits, damage to brand value due to reputational harm, costs incurred for response). If the NDA includes a penalty clause, that amount can be claimed. If the value of the share capital or fund repayment in a medical corporation is deemed to have been diminished by the information leak, the reduction in value may also be claimed as damages.
However, calculating the amount of damages requires specialized knowledge and evidence, making it essential to proceed with appropriate procedures in cooperation with lawyers and M&A advisors. Including clear provisions for measures in case of breach in the NDA to serve as a deterrent is also extremely important from a risk management perspective.
Role of Specialized Advisors in Medical M&A
Medical M&A requires specialized knowledge and experience that differs from general corporate M&A. Especially concerning confidentiality, the presence of specialized advisors who deeply understand the delicate circumstances unique to the medical industry is indispensable.
Confidentiality Support Provided by M&A Advisors
M&A advisors specializing in medical M&A, such as M&A Medical, provide multifaceted support from a confidentiality perspective, including:
- Appropriate Design and Signing Support for NDAs: Support the drafting of NDA clauses that consider the characteristics of the medical industry and assist in concluding fair and effective agreements for both seller and buyer. In particular, provide specific advice on identifying the scope of information to be protected and measures in case of breach.
- Management of Information Disclosure Process: Formulate a phased information disclosure plan, determining what information to disclose, when, to whom, and to what extent, and support its execution. Provide advice based on extensive experience regarding the timing and content of notifications to internal stakeholders.
- VDR Implementation and Operation Support: Provide comprehensive support from VDR selection to implementation and operation for secure information sharing. Ensure information security from a technical standpoint, such as setting access rights and thoroughly managing logs.
- Ensuring Anonymity: In the initial stages, proceed with matching using only anonymized information such as region, specialty, and scale, without identifying the medical institution’s name. This minimizes the risk of inadvertent information leaks.
- Consideration for Unique Medical Industry Circumstances: Appropriately manage confidential information based on specific issues in medical M&A, such as medical corporation types (with/without share capital), procedures for changing members, requirements for fund repayment, impact of medical fee revisions, maintenance of facility standards, transfer of licenses and permits, complex handling of business taxes and capital gains tax, and alignment with regional healthcare plans.
- Risk Management and Emergency Response: Consider countermeasures in advance in case of an information leak and provide advice for prompt initial response and prevention of damage escalation.
M&A Medical, as an M&A support institution certified by the Small and Medium Enterprise Agency, has institutionalized systems for conflict of interest management and information management, and supports clients’ M&A with high ethical standards and expertise. To achieve successful M&A of a medical institution, it is essential to understand the importance of confidentiality and proceed with thorough preparation in cooperation with experts.
M&A and business succession of medical institutions are crucial choices that support future regional healthcare. Confidentiality serves as the foundation for smoothly and safely advancing this important process. When considering M&A for your own medical institution, please consult with a specialist in medical M&A. M&A Medical offers initial free consultations. We will propose the optimal M&A strategy under thorough information management, including the conclusion of Non-Disclosure Agreements (NDAs), so please feel free to contact us.
For consultations on medical succession, contact M&A Medical
M&A Medical is a specialized M&A and business succession support service for medical institutions. As an M&A support institution certified by the Small and Medium Enterprise Agency, we support the success of transfers of clinics and medical corporations facing succession issues, as well as strategic acquisitions, on a success-fee basis.
- Initial consultation and preliminary assessment are free
- No upfront fees or monthly charges (success fee only)
- Strict confidentiality (proceeding after signing NDA)
- Support for all 47 prefectures and all medical specialties
Please consult with us early, even in the initial stages of consideration, whether you just want to know the market price, have no successor, or are considering joining a group.